HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: CJN.01520209v1 4/9/1409    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Google Scholar Articles by Kengne, S.-W. Articles by Emma, F. PubMed PubMed Citation Articles by Kengne, S.-W. Articles by Emma, F.

Risk Factors for Cyclosporin A Nephrotoxicity in Children with Steroid-Dependant Nephrotic Syndrome

Severin-Wafo Kengne^*, Laura Massella^*, Francesca-Camassei Diomedi, Alessandra Gianviti^*, Marina Vivarelli^*, Marcella Greco^*, Gilda Stringini Rita^*, and Francesco Emma^*

Divisions of ^* Nephrology and Dialysis and Pathology, Bambino Gesù Children's Hospital and Research Institute, Rome, Italy

Correspondence: Dr. Francesco Emma, Department of Nephrology and Urology, Division of Nephrology and Dialysis, Ospedale Bambino Gesù, IRCCS, Piazza S. Onofrio, 4, 00165 Rome, Italy. Phone: +390668592126; Fax: +390668592602; E-mail: emma{at}opbg.net

Background and objectives: Cyclosporin A (CsA) is a well-established treatment for steroid-dependent nephrotic syndrome (SDNS) that may, however, cause chronic ischemic renal lesions. The objective of the study was to assess the prevalence of CsA nephrotoxicity (CsAN) in protocol biopsies of children with SDNS.

Design, settings, participants, & measurements: From 1990 through 2008, we performed 71 renal biopsies in 53 patients with SDNS. The mean CsA C2 levels were 466 ± 134 ng/ml, and the mean duration of treatment was 4.7 ± 2.0 yr before biopsy (range 2.9 to 12.7 yr).

Results: CsAN was observed in 22 (31%) of 71 renal biopsies. Of these, 11 corresponded to isolated vascular or tubular lesions, and 11 corresponded to combined vascular and tubular lesions. The majority of CsAN lesions were mild (17 of 22). In no cases were lesions graded as severe. By regression analysis, CsAN was positively associated with the use of angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs) and with hyperuricemia and negatively associated with minimal-change lesions. By multivariate analysis, only association with the use of ACEIs or ARBs retained significance. Stratification of the population according to CsA C2 levels showed increased risk for CsAN for C2 levels >600 ng/ml.

Conclusions: Mild to moderate CsAN occurs in approximately one third of patients who have SDNS and are treated with CsA for >3 yr. Our data suggest that patients who require high dosages of CsA or treatment for hypertension, in particular when ACEIs/ARBs are used, are at higher risk for CsAN.